The company said Wednesday that Collis is slated to become chairman upon Gozon’s retirement at AmerisourceBergen’s annual shareholders meeting on March 3, 2016. Also at the meeting, current board member Jane Henney, M.D., will become lead independent director.
Collis’ and Henney’s elections to the new roles are contingent on their re-election as directors at the annual meeting of stockholders, AmerisourceBergen added.
“With his unparalleled knowledge of the company and industry, Steve is uniquely positioned to lead AmerisourceBergen as it moves forward and to fulfill the company’s long-term strategic objectives and expansion into new markets,” Gozon said in a statement. “His strategy has built, and will continue to build, value for shareholders.”
Collis has been served as president and CEO of AmerisourceBergen since July 2011 and has been a board director since May 2011. Henney has been a director since January 2002 and has served as chair of the governance and nominating committee since June 2009.
“Jane’s integrity, experience as a director of public companies, including at Cigna Corp., AstraZeneca plc and Cubist Pharmaceuticals Inc., commitment to governance best practices and leadership of the governance and nominating committee made her a clear choice to take on the role of lead independent director,” Gozon commented.
Gozon joined the AmerisourceBergen board as a director in August 2001 and has been chairman since February 2006.
“I want to thank Dick for his extraordinary dedication to AmerisourceBergen and the outstanding leadership and guidance that he has provided as chairman,” Collis stated. “While we will miss him greatly, Dick’s legacy will be lasting.”